ARGX
NASDAQargenx SE
Price$1007.69+3.07 (+0.31%)
01:30 PM07:45 PM
News · 26 weeks46-23%
2026-03-152026-09-06
Mix2690d
- SEC Filings10(38%)
- Other7(27%)
- Earnings5(19%)
- Analyst3(12%)
- M&A1(4%)
Latest news
25 items- PRargenx to Present at Upcoming Investor ConferencesSeptember 1, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor conferences in September: Wells Fargo 21st Annual Healthcare Conference. Fireside chat on Tuesday, September 8, 2026 at 9:30 a.m. ET in Boston, MA.Morgan Stanley 24th Annual Global Healthcare Conference. Fireside chat on Monday, September 14, 2026 at 9:15 a.m. ET in New York, NY. A live webcast of the presentations may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcasts will be available on the argenx website for approx
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- SECAmendment: SEC Form SC TO-T/A filed by argenx SESC TO-T/A - ARGENX SE (0001697862) (Filed by)
- PRargenx Completes Acquisition of Forte Biosciences, Inc.Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx’s immunology pipeline August 27, 2026 – 8:50 AM ET Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology innovation company today announced the successful completion of the acquisition of Forte Biosciences, Inc. ("Forte") (NASDAQ:FBRX). The acquisition expands argenx’s portfolio of differentiated immunology medicines, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune diseases. The acquisition reflects argenx’s disciplined approach to identifying and advancing breakthrough science fo
- ANALYSTargenx upgraded by UBS with a new price targetUBS upgraded argenx from Neutral to Buy and set a new price target of $1,400.00
- ANALYSTargenx downgraded by Deutsche BankDeutsche Bank downgraded argenx from Buy to Hold
- SECAmendment: SEC Form SC TO-T/A filed by argenx SESC TO-T/A - ARGENX SE (0001697862) (Filed by)
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRZai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune MyositisStudy met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM First Phase 3 study to show statistically significant and clinically meaningful improvements in disease activity in IMNM, a subtype with no approved therapy Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) and argenx ((Euronext &, NASDAQ:ARGX), today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis. Study met
- PRargenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune MyositisStudy met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011)Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM First Phase 3 study to show statistically significant and clinically meaningful improvements in disease activity in IMNM, a subtype with no approved therapy argenx to host a conference call on August 17th at 2:30 PM CET/ 8:30 AM ET August 17, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology innovation company, today announced positive topline results from the ALKIVIA Phase 3 stud
- SECAmendment: SEC Form SC TO-T/A filed by argenx SESC TO-T/A - ARGENX SE (0001697862) (Filed by)
- PRargenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.August 6, 2026 – 7:45 AM ET Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology innovation company today announced that Avena Merger Sub Inc. ("Purchaser"), a wholly-owned subsidiary of argenx BV ("argenx"), has commenced a tender offer to purchase all of the issued and outstanding shares of Common Stock, par value $0.001 per share (the "Shares"), of Forte Biosciences, Inc. ("Forte") (NASDAQ:FBRX), for $77.00 per Share, net to the seller in cash, without interest, subject to any applicable withholding taxes, and upon the terms and subject to the conditions set forth in the Offer to Purchase, dated August 6, 2026, and the accompanying Letter of Transmittal (to
- SECSEC Form SC TO-T filed by argenx SESC TO-T - ARGENX SE (0001697862) (Filed by)
- ANALYSTGuggenheim resumed coverage on argenx with a new price targetGuggenheim resumed coverage of argenx with a rating of Buy and set a new price target of $1,185.00
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx announces Extraordinary General Meeting of Shareholders on September 17, 2026August 3, 2026 – 22:01 PM CEST Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of Shareholders will be held at 15:00 CEST on Thursday, September 17, 2026 at the offices of Freshfields LLP (Netherlands), Strawinskylaan 10, 1077 XZ Amsterdam, the Netherlands.The shareholders and all other persons entitled to attend the Extraordinary General Meeting are invited to attend. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notific
- SECSEC Form SC TO-C filed by argenx SESC TO-C - ARGENX SE (0001697862) (Filed by)
- SECSEC Form SC TO-C filed by argenx SESC TO-C - ARGENX SE (0001697862) (Filed by)
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology PipelineTransaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth FB102 Phase 1b studies in vitiligo and celiac disease validate CD122 biology and pipeline-in-a-product potential to address diseases with high unmet need that have lacked innovation Acquisition strengthens argenx’s innovative immunology portfolio with the addition of a differentiated approach to targeting pathogenic T-cell and NK-cell activity through CD122 biology argenx will host an investor conference call today at 8:00 a.m. ET to discuss the transaction argenx ((Euronext &, NASDAQ:ARGX), a global immunol
- PRargenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology PipelineTransaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growthFB102 Phase 1b studies in vitiligo and celiac disease validate CD122 biology and pipeline-in-a-product potential to address diseases with high unmet need that have lacked innovationAcquisition strengthens argenx’s innovative immunology portfolio with the addition of a differentiated approach to targeting pathogenic T-cell and NK-cell activity through CD122 biologyargenx will host an investor conference call today at 8:00 a.m. ET to discuss the transaction July 27, 2026 – 7:00 AM CET Amsterdam, the Netherlands and Dalla
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business UpdateStrong second quarter performance with $1.5 billion in global product net sales, representing 60% year-over-year growth and 17% quarter-over-quarter growth Successfully launched VYVGART and VYVGART Hytrulo in anti-AChR antibody negative ("seronegative") gMG, expanding patient reach to all gMG serotypes Registrational autoimmune myositis study readout on track for 3Q26, marking a key milestone for VYVGART expansion into rheumatology Registrational MMN study readout for empasiprubart on track for 4Q26, supporting a second pipeline-in-a-product opportunity Management to host conference call today at 2:30 PM CET (8:30 AM ET) July 23, 2026 7:00 AM CET Amsterdam, the Netherlands - argenx
- PRargenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026July 16, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 23, 2026 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2026 financial results and provide a second quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Participants can access the conference call by dia
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
ARGX FAQ
7 questionsWhat does argenx SE do?
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with...Where does ARGX stock trade?
argenx SE (ARGX) is listed on NASDAQ.What sector and industry is ARGX in?
argenx SE operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did argenx SE go public?
argenx SE (ARGX) completed its IPO in 2017.What are analysts saying about ARGX?
argenx SE has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-08-26.What companies are similar to ARGX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ARGX side-by-side with any of them on Quantisnow.How can I track ARGX on Quantisnow?
Quantisnow aggregates argenx SE's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARGX to receive live email and push alerts on every new disclosure.